Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Marinus Pharma CS (NQ: MRNS ) 1.670 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Oct 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Marinus Pharma CS < Previous 1 2 3 4 5 6 7 8 9 10 11 Next > Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst Day September 20, 2024 From Marinus Pharmaceuticals Via Business Wire Marinus Pharmaceuticals Announces Agenda and Speakers for Investor & Analyst Day on September 20, 2024 September 12, 2024 From Marinus Pharmaceuticals Via Business Wire Marinus Pharmaceuticals to Present at the 2024 Cantor Global Healthcare Conference September 10, 2024 From Marinus Pharmaceuticals Via Business Wire Marinus Pharmaceuticals to Host Investor and Analyst Day on Friday, September 20, 2024 August 19, 2024 From Marinus Pharmaceuticals Via Business Wire MRNS Stock Earnings: Marinus Pharma Misses EPS, Misses Revenue for Q2 2024 August 13, 2024 MRNS stock results show that Marinus Pharma missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. Via InvestorPlace Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results August 13, 2024 From Marinus Pharmaceuticals Via Business Wire 3 Biotech Stocks to Sell in August Before They Crash & Burn August 06, 2024 Investors should keep a watchful eye out for these three biotech stocks to sell before a potential dip damages their gains. Via InvestorPlace MRNS Investors Have Opportunity to Join Marinus Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm August 05, 2024 From The Schall Law Firm Via Business Wire Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Marinus, 2U, Teradata, and Lamb Weston and Encourages Investors to Contact the Firm August 02, 2024 From Bragar Eagel & Squire Via GlobeNewswire The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Marinus Pharmaceuticals, Inc. (MRNS) August 02, 2024 From The Law Offices of Frank R. Cruz Via Business Wire MRNS Investors Have Opportunity to Join Marinus Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm August 02, 2024 From The Schall Law Firm Via Business Wire SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Marinus August 02, 2024 From Faruqi & Faruqi LLP Via GlobeNewswire MRNS DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages Marinus Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 5 Deadline in Securities Class Action First Filed by the Firm – MRNS August 02, 2024 From The Rosen Law Firm PA Via GlobeNewswire MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm August 01, 2024 From The Schall Law Firm Via Business Wire Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Marinus, 2U, Humana, and Lamb Weston and Encourages Investors to Contact the Firm July 31, 2024 From Bragar Eagel & Squire Via GlobeNewswire MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm July 30, 2024 From Schall Law Via GlobeNewswire Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2024 Financial Results on August 13, 2024 July 30, 2024 From Marinus Pharmaceuticals Via Business Wire MRNS DEADLINE: TOP RANKED ROSEN LAW FIRM Encourages Marinus Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 5 Deadline in Securities Class Action First Filed by the Firm – MRNS July 29, 2024 From The Rosen Law Firm PA Via GlobeNewswire MARINUS PHARMACEUTICALS, INC. (NASDAQ: MRNS) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Marinus Pharmaceuticals, Inc. Investors of Upcoming Deadline July 29, 2024 From Bernstein Liebhard LLP Via GlobeNewswire DEADLINE NEXT WEEK: Berger Montague Advises Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) Investors to Contact the Firm Before August 5, 2024 July 29, 2024 From Berger Montague Via GlobeNewswire Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Marinus, 2U, Humana, and Lamb Weston and Encourages Investors to Contact the Firm July 27, 2024 From Bragar Eagel & Squire Via GlobeNewswire SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Marinus July 26, 2024 From Faruqi & Faruqi LLP Via GlobeNewswire Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Marinus, 2U, and Lamb Weston and Encourages Investors to Contact the Firm July 23, 2024 From Bragar Eagel & Squire Via GlobeNewswire MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm July 23, 2024 From Schall Law Via GlobeNewswire MARINUS PHARMACEUTICALS, INC. (NASDAQ: MRNS) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Marinus Pharmaceuticals, Inc. Investors of Upcoming Deadline July 22, 2024 From Bernstein Liebhard LLP Via GlobeNewswire ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Marinus Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – MRNS July 20, 2024 From The Rosen Law Firm PA Via GlobeNewswire Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Marinus, 2U, and Lamb Weston and Encourages Investors to Contact the Firm July 18, 2024 From Bragar Eagel & Squire Via GlobeNewswire SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Marinus July 18, 2024 Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Marinus To Contact Him Directly To Discuss Their Options From Faruqi & Faruqi LLP Via GlobeNewswire Marinus Pharmaceuticals Announces Ganaxolone Approved in China as First Treatment for Seizures Associated with CDKL5 Deficiency Disorder July 18, 2024 From Marinus Pharmaceuticals Via Business Wire ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Marinus Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – MRNS July 17, 2024 From The Rosen Law Firm PA Via GlobeNewswire < Previous 1 2 3 4 5 6 7 8 9 10 11 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.